Top Markets
#1 龙虾 (Lobster) 龙虾 (Lobster) +117.81%
#2 Lisk Lisk +81.56%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +30.37%
#4 Tokenlon Tokenlon +28.92%
#5 Alchemist AI Alchemist AI +28.02%
#6 Nockchain Nockchain +25.68%
#7 earnAUSD earnAUSD +24.75%
#8 Renzo Renzo +21.89%
#9 Illuvium Illuvium +19.74%
#10 Akedo Akedo +18.38%
Coin of the day
龙虾 (Lobster) 龙虾 (Lobster)
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
MultiCell Technologies, Inc. MultiCell Technologies, Inc.

MultiCell Technologies, Inc.

MCET
Clasificación en acciones #41009
MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm,... MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm, primarily focused on the creation of innovative therapeutic agents and research tools. Their efforts are directed towards addressing a range of medical challenges, including neurological conditions, liver ailments, various types of cancer, and applications within interventional cardiology and peripheral vascular health. The company's product pipeline features several key developments: MCT-125: This investigational therapy is currently in Phase II clinical trials, targeting the primary fatigue commonly associated with multiple sclerosis. MCT-465: A preclinical-stage synthetic double-stranded RNA (dsRNA) candidate, designed to act as a powerful immune enhancer for the treatment of solid tumor malignancies. MCT-485: Another dsRNA therapeutic, still in the discovery phase, which demonstrates tumor cytolytic (cell-destroying) properties, intended for use against diverse cancers. Beyond drug candidates, MultiCell Technologies is also progressing the Ideal BioStent, an innovative bioabsorbable stent specifically engineered for use in interventional cardiology and peripheral vessel procedures. The organization maintains licensing agreements with prominent entities such as Corning Incorporated and Pfizer Inc. Established in 1962, the company was previously known as Exten Industries, Inc. before officially changing its name to MultiCell Technologies, Inc. in April 2004. Its corporate headquarters are situated in Woonsocket, Rhode Island.
Precio por acción
$0.00001
Última sincronización: 2026-09-10
Capitalización bursátil
$50.01K
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio MultiCell Technologies, Inc. (MCET)

Categoría

Healthcare
Ingresos de MultiCell Technologies, Inc. (MCET)
Ingresos en Aug 2015 TTM: $805.24
Según los últimos informes financieros de MultiCell Technologies, Inc., los ingresos actuales de la empresa (TTM) son $805.24. En 2013, la empresa obtuvo unos ingresos de $49.32 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de MultiCell Technologies, Inc. desde 2013 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
2026 (TTM) $805.24 1,532.68%
2014 $49.32 0.00%
2013 $49.32 0.00%
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 1,567,776,303.44%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 747,766,680.05%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 276,688,970.04%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 1,955,243,721.94%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH